The potential role of germline single nucleotide polymorphisms for selecting the ideal candidates for sunitinib therapy in patients with locally-advanced renal cell carcinoma

Renal cell carcinoma (RCC) represents the eighth most common malignant cancer diagnosed in the United States (1). Despite a stage migration of RCC towards a more localized disease over the past decades, a considerable proportion of patients is still diagnosed with loco-regional disease. In case of organ-confined RCC, the overall prognosis for surgically treated patients is fairly good, with a 5-year cancer specific mortality (CSM)-free rate of 91% and for stage I (T1N0M0) and 74% for stage II (T2N0M0).